a friend of mine at MIT, which is a big purchaser of affymetrix equipment, said they have zero intention of buying the genetitan for genotyping when it becomes available this year.
he said no one cares about genotyping anymore, genetitan is about 4 years too late to the game compared to illumina, most labs are already stocked with illumina genotyping machines, and all the money is going to next generation sequencing.
from Leerink's analyst, Isaac Ro. He's arguing that Illumina's new Harmonia platform is a problem for Genetitan. report out today:
"we think Harmonia could also pose a risk to AFFX's new GeneTitan platform. Using Harmonia, existing ILMN array users will in theory be able to supplant the use of legacy expression arrays thanks to a far lower equipment and IT burden versus the standard GA system. As AFFX has yet to launch genotyping arrays on GeneTitan, we think a timely launch of Harmonia could be challenging for AFFX. To a lesser extent, we also believe Harmonia could impact LIFE's ability to continue winning market share at smaller institutions. Price and ease of use is always a factor and we believe Harmonia's ability to interface with iScan and offer array functionality as well could be the Trojan Horse for ILMN in this segment of the market."
market hype to - they call it walk away automation, but the hardest step, with the most variability - target prep - is still manual !!! and, their server is slow - took forever to downlaod a simple 5 Mb pdf file (which is about 4.9 Mb of market fluff, and a few kb of text info)